Keros Therapeutics, Inc. 8-K

What Happened

• On June 3, 2026 Keros Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders (a quorum was present) and filed an 8-K reporting the voting results. Stockholders elected two directors (terms through the 2029 Annual Meeting), ratified Deloitte & Touche LLP as the company's independent registered public accounting firm for fiscal 2026, and approved, on a non-binding advisory basis, the company's executive compensation disclosure.

Key Details

• Director elections:
  • Jean‑Jacques Bienaimé elected: 10,093,559 votes for; 5,156,153 withheld; 2,243,514 broker non‑votes.
  • Charles Newton elected: 14,716,598 votes for; 533,114 withheld; 2,243,514 broker non‑votes.
• Auditor ratification (Proposal 2): Deloitte & Touche LLP approved — 16,708,279 for; 783,953 against; 994 abstain. (No broker non‑votes.)
• Advisory vote on executive compensation (Proposal 3): Approved — 14,273,625 for; 974,049 against; 2,038 abstain; 2,243,514 broker non‑votes.

Why It Matters

• These governance votes confirm the board composition through 2029 and maintain auditor continuity for fiscal 2026, both of which affect oversight and financial reporting.
• The advisory approval of executive compensation signals shareholder support for the company's pay practices as disclosed in its proxy (though the vote is non‑binding).
• The presence of substantial broker non‑votes on director and say‑on‑pay matters indicates a portion of shares held in street name did not provide votes, which can affect the vote margins investors should watch in future governance items.